Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anal incontinence17.05.01.021; 07.01.06.0290.000168%
Liver function test increased13.03.04.031--Not Available
Abdominal mass07.01.01.0030.000168%Not Available
Anal ulcer07.04.01.0010.000112%
Aortitis24.12.01.0010.000224%Not Available
Apnoeic attack22.02.01.027; 17.02.05.0510.000112%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.000168%Not Available
Bronchial carcinoma16.19.02.004; 22.08.01.0150.000246%Not Available
Cerebral haemorrhage neonatal24.07.04.024; 18.04.16.001; 17.08.01.0480.000168%Not Available
Coronary artery aneurysm24.02.02.005; 02.02.01.0120.000224%Not Available
Extravasation blood24.07.01.0670.000112%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.025--Not Available
Malignant pleural effusion16.32.03.014; 22.05.04.0010.000168%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.000392%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000224%Not Available
Metastases to skin23.07.04.026; 16.22.02.0230.000112%Not Available
Monocytopenia01.02.02.0050.000112%Not Available
Mononeuropathy multiplex17.09.02.0120.000280%Not Available
Non-small cell lung cancer stage IV22.08.01.022; 16.19.01.0100.000112%Not Available
Pancreatic carcinoma metastatic16.13.10.003; 07.21.09.0060.004723%Not Available
Scleroderma-like reaction23.03.02.019; 15.06.01.018; 10.04.07.0050.000392%Not Available
Threatened labour18.07.01.0090.000112%Not Available
Urogenital fistula21.10.05.019; 20.08.01.0130.000112%Not Available
Terminal state08.01.03.0790.000112%Not Available
Subclavian vein thrombosis24.01.02.0130.000112%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000112%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.002597%Not Available
Biliary dilatation09.02.03.0040.000112%Not Available
Cell death14.11.02.005; 08.03.03.0030.000224%Not Available
Metastatic carcinoma of the bladder20.03.04.006; 16.08.01.0040.000112%Not Available
The 25th Page    First    Pre   25 26 27    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene